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CancerAbstract Background: Access to narcotics has been described as suboptimal in the Middle East.
The objectives of this study were to characterize estimated narcotic use in twelve Arabic-speaking
nations and compare across world regions.
Methods: This was a population-based cross-sectional analysis of estimated average
consumption of narcotic drugs in defined daily doses per million inhabitants, as provided by the
International Narcotics Control Board Technical Reports (2008–2012). Five years of data
(2008–2012) were extracted from reports for 12 Arabic-speaking countries: Lebanon, Jordan, Syria,
Qatar, United Arab Emirates, Saudi Arabia, Oman, Bahrain, Kuwait, Iraq, Egypt, and Yemen.
Data were also obtained for world regions.
Results: In 2012, Bahrain and Kuwait had the highest estimates (364 and 352 defined daily doses
per million inhabitants per day, respectively), while Yemen and Iraq had the lowest (9 and 6 defined
daily doses per million inhabitants per day, respectively). North America, Oceania, and Europe had
the highest rates (32,264, 9978, and 7937 defined daily doses per million inhabitants per day, respec-
tively), while Arabic-Countries were only ahead of Africa and Central America (128, 91, 87 defined
daily doses per million inhabitants per day, respectively).
Conclusions: Great variability was observed in estimates between 12 Arabic countries and even
larger disparity when Arabic-Countries were benchmarked against world regions, suggesting a need
for future studies to determine reasons for these discrepancies.
 2016 Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Patterns and trends in drug utilization fuel high-level decisions
in both public and private settings (WHO, 2003; Dodoo et al.,
2009). Governments may use data to alter funding programs,
while other entities may use data to produce generic medicines
or fund research programs relating to highly used drug classese Middle
Table 1 Narcotic drug and defined daily dose (mg) as per
INCB (INCB, 2015).
Narcotic drug Defined daily dose (mg)
Acetyldihydrocodeine 40
Alphaprodine 120
Anileridine 65
Bezitramide 15
Codeine (cough suppressant) 100
Codeine (analgesic) 240
Dextromoramide 20
Dextropropoxyphene hydrochloride 200
Dextropropoxyphene napsylate 300
Difenoxin 3
Dihydrocodeine (cough suppressant) 100
Dihydrocodeine (analgesic) 150
Diphenoxylate 15
Dipipanone 75
Ethylmorphine 50
Fentanyl 0.6
Heroin 30
Hydrocodone 15
Hydromorphone 20
Ketobemidone 50
Levorphanol 6
Methadone 25
Morphine 100
Nicomorphine 30
Normethadone 10
Norpipanone 18
Opium 100
Oxycodone 75
Oxymorphone 10
Pethidine 400
Phenazocine 20
Phenoperidine 4
Pholcodine 50
Piminodine 100
Piritramide 45
Propiram 100
Thebacon 15
Tilidine 200
Trimeperidine 200
2 K.J. Wilby, K. Wilbur(WHO, 2003; Schneeweiss and Avorn, 2005). Characterizing
this information is essential for monitoring health and eco-
nomic outcomes of such decisions over time. These data can
also be used to assess the potential impact of world events,
publication of influential clinical trials, media reports, or other
considerations that affect medication usage in society (Lee and
Bergman, 2012). International comparisons of utilization data
provide benchmarking opportunities for countries to assess
regional and global trends, as well as signaling suboptimal or
overuse of target medications.
Drug utilization is determined by a number of factors,
including disease prevalence, prescriber habits, patient demand
and access to medications (Bradley, 1992). Other patient-level
characteristics such as education, socioeconomic status, cul-
tural beliefs, and even geographical region may also influence
patterns of use (Bradley, 1992; Vermeire et al., 2001; Chia
et al., 2006). Cross-national trending allows for identification
of signals that may warrant further study of these conditions.
Recently, there has been an increase in published literature
describing cross-national trends in drug utilization for a vari-
ety of drug classes (Feng et al., 2009; Wilby et al., 2013;
Mamdani and Wilby, 2013). Despite well-established roles
for rational opioid prescribing in the management of pain
states, utilization of narcotic medications has often been sub-
ject to scrutiny due to real risks of addiction, dependence,
and diversion for illicit use (Zacny et al., 2003). However, little
is known from a cross-national perspective, including coun-
tries in the Middle East.
The Middle East is representative of a region that greatly
varies in both population and wealth, with many countries,
especially those belonging to the Gulf Cooperation Council
(GCC), enjoying recent affluence due to natural resource inter-
ests. Qatar is one such country having recently launched plans
to address several deficit areas in the health system, notably
medication and patient safety issues. Specifically, the current
Qatar National Health Strategy has outlined the need to
educate health professionals regarding appropriate use of
narcotics as inadequate pain management approaches has
resulted in opioid administration almost exclusive to
inpatient-based care settings (Qatar National Health
Strategy, 2014). It is unknown whether this pattern occurs
throughout the Middle Eastern region, or is limited to Qatar
and other GCC countries. Prior work has described palliative
care initiatives in Qatar; however, there is a scarcity of pub-
lished experience among other countries and across additional
suitable medical indications to fully determine the overall/
general status of opioid prescribing in the region (Bingley
and Clark, 2009; Charalambous et al., 2012; Al-Kindi et al.,
2013; Abu Zeinah et al., 2013).
In order to provide a baseline assessment of narcotic uti-
lization in Arabic-speaking countries, our objective was to
characterize narcotic use in twelve Arabic-speaking nations
located in the GCC and surrounding Middle Eastern nations.
We also sought to explore and compare Middle East narcotic
use with other geographical regions.
2. Methods
Annual narcotic utilization estimates were used for analysis.
These estimates are generated according to each country’s
actual utilization data obtained from the prior three yearsPlease cite this article in press as: Wilby, K.J., Wilbur, K. Cross-national analysis of e
East. Saudi Pharmaceutical Journal (2016), http://dx.doi.org/10.1016/j.jsps.2016.01.and are self-reported. For example, the 2013 estimates incor-
porated actual utilization data obtained from 2009 through
2011. Data were obtained from the International Narcotics
Control Board (INCB) Narcotic Drugs – Technical Reports
which are freely available online (INCB, 2015). Each annual
report compiles member countries’ estimates of their national
narcotic requirements for the subsequent year.
Annual estimates are given as average consumption of nar-
cotic drugs in defined daily doses per million inhabitants per
day. The opioids included in this estimate are listed in Table 1.
For ease of comparison, the INCB transforms overall drug
weight estimates into defined daily doses and the doses used
for this transformation are also given in Table 1. It is impor-
tant to note that this transformation occurs for statistical pur-
poses only and does not necessarily reflect the usual prescribed
dose for each agent. However, it allows for a means of compar-
ison between agents that accounts for differences in drug
potency. It is also the best measure to assess countries, such
as those in the Middle East, where actual prescribing data
are unavailable.stimated narcotic utilization for twelve Arabic speaking countries in the Middle
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Figure 2 Worldwide comparisons of estimated narcotic require-
ments by geographical region (defined daily doses per million
inhabitants per day vs. year).
Cross-national analysis of estimated narcotic utilization 3Five years of data (2008–2012) were extracted from reports
for 12 Arabic-speaking countries located within the Middle
East region: Bahrain, Egypt, Iraq, Jordan, Kuwait, Lebanon,
Oman, Qatar, Saudi Arabia, Syria, United Arab Emirates
and Yemen. Data for Iraq were not available in 2008. Annual
narcotic utilization estimates extracted from each country’s
INCB report were evaluated and an additional category,
labeled Arabic Countries and comprised of all these nations,
was calculated to facilitate further international comparisons.
Data for the annual narcotic estimates available in the 2010,
2011, and 2012 INCB reports were obtained for other world
regions (Africa, Asia, Central America, Europe, North Amer-
ica, Oceania, and South America).
Once data were extracted, we conducted a population-
based cross-sectional analysis of estimated average consump-
tion of narcotic drugs in defined daily doses per million
inhabitants, as defined by INCB. The primary outcome of this
study was to report the annual estimate of narcotic drugs for
each country or region. A secondary outcome was the rate
of growth of estimated annual narcotic drugs per country or
region. This study was approved by the Institutional Review
Board at Qatar University.
3. Results
3.1. Comparison of Arabic speaking countries
In 2012 (2013 estimate), the Gulf States of Bahrain and
Kuwait had the highest estimates (364 and 352 defined daily
doses per million inhabitants per day, respectively), while
Yemen and Iraq had the lowest estimates (9 and 6 defined daily
doses per million inhabitants per day, respectively) (Fig. 1).
Resource-rich countries such as Saudi Arabia, Qatar, and
UAE had average estimates (250, 198, and 215 defined daily
doses per million inhabitants per day, respectively). All coun-
tries had positive rates of growth, except Jordan and Lebanon
(1.75, 16.25 defined daily doses per million inhabitants per
day, respectively). The countries with the highest rates of
growth were again, Kuwait and Bahrain (52.75 and 43.75
defined daily doses per million inhabitants per day,
respectively).0
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Figure 1 Estimated narcotic requirements for the 12 Arabic
speaking countries in the Middle East (defined daily doses per
million inhabitants per day vs. year).
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There were substantial differences observed between world
regions in narcotic utilization from 2010 through 2012 (see
Fig. 2). The regions of North America, Oceania, and Europe
had the highest observed values (32,264, 9978 and 7937 defined
daily doses per million inhabitants per day, respectively). South
America and Asia had slightly higher values (253 and 231
defined daily doses per million inhabitants per day, respectively)
than Africa and Central America (91 and 87 defined daily doses
per million inhabitants per day, respectively) in 2012. When the
12 Arabic-speaking countries were pooled, the calculated esti-
mate was lower than all regions except for Africa and Central
America (128 defined daily doses per million inhabitants per
day). Of note, the only regions with declining rates in narcotic
requirement estimates were North America and Arabic-
speaking countries (191.5 defined daily doses per million
inhabitants per day and 26.1 defined daily doses per million
inhabitants per day, respectively). The highest growth rates
were observed in Oceania and Europe (745.5 defined daily doses
permillion inhabitants per day and 680.5 defined daily doses per
million inhabitants per day, respectively).
4. Discussion
This study assessed estimated narcotic requirements in 12
Arabic-speaking countries in the Middle East and compared
these requirements to other geographic regions in the world.
Great variability was found among these Arabic-speaking
countries, with Kuwait and Bahrain having the highest esti-
mates. Similarly, these two countries had the highest rates of
growth in estimates from 2008 through 2012. When compared
to seven other global regions, Arabic-speaking countries in the
Middle East had one of the lowest estimates of annual narcotic
requirements, only higher than Africa and Central America.
Arabic-speaking countries, along with North America, had
the only negative growth rate in estimates from 2010 through
2012.
These findings imply patient access to opioid therapy in the
Middle East is disparate from most other places in the worldstimated narcotic utilization for twelve Arabic speaking countries in the Middle
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low estimates, relative to other regions, are not clear, yet
patient health outcomes may be aversely influenced.
Inadequate pain control is known to lead to other chronic
medical problems such as anxiety and depression and is asso-
ciated with higher rates of addiction and dependence
(Cleeland, 1984). Productivity may decrease, due to increased
recovery times from poor mobilization and rehabilitation
(Cohen et al., 2004). These considerations would also heavily
burden healthcare systems in terms of patient management
and disposition of care. As such, studies assessing low esti-
mated narcotic use with patient-level outcomes are needed to
establish baseline understanding of the importance of these
implications in practice.
This study raises important points regarding the rationale
for low narcotic use in Arabic-speaking countries versus other
world regions. Culture and religious explanations have been
previously suggested and should be further explored (Qatar
National Cancer Strategy, 2011–2016). These countries
predominantly follow Islamic principles, laws, and customs.
Narcotic prescribing and/or consumption may be greatly influ-
enced by religion, especially in situations where multiple non-
opioid analgesic choices exist. Even when deemed medically
necessary, considerations of prescribers or their patients may
limit appropriate narcotic use by choice of drug, dose, or dura-
tion of therapy. For example, a survey of senior medical stu-
dents completing their study in Saudi Arabia found poor
knowledge and antiquated attitudes regarding opioid analgesia
prescribing; nearly half considered pain a minor problem for
cancer patients (41%) and believed it to be untreatable
(46%). Sixty-eight percent limited opioid prescribing to
patients with poor prognosis (Kaki, 2011). It is also possible
that cultural positions may influence governments and regula-
tory bodies when developing policies and procedures restrict-
ing use of narcotics in practice. Studies are needed to further
explore these considerations and to determine facilitators
and barriers for optimizing use.
Observed discrepancies in estimated narcotic requirements
between Arabic-speaking countries are also of concern.
Affluent countries, such as GCC member states (Bahrain,
Kuwait, Oman, Qatar, Saudi Arabia, United Arab Emirates),
are investing efforts to develop world-class health systems
based on Western standards and could be credited to the
higher utilization rates among these countries. Iraq and Yemen
had the lowest estimates, which may be a reflection of political
instability present during the years of study (Size et al., 2007).
The low estimates for Egypt may potentially be explained in
part by previous reports commenting on the limited accessibil-
ity and availability of narcotics for medical use (Alsirafy et al.,
2012). Of course, country-specific laws and regulations regard-
ing narcotic manufacturing, importation, and distribution will
also greatly influence utilization patterns. Governmental-level
concerns of addiction and abuse risk may foster system-wide
disincentives for appropriate opioid prescribing (such as com-
pelling physicians to submit to a health ministry the patient
documentation for each narcotic prescription). Costs of
importing opioid agents to developing countries may also be
prohibitive.
The findings of this study are important for future research.
As suggested above, studies are needed to determine whether
associations exist between low narcotic utilization and poor
patient outcomes. Additionally, rationale for the findings mustPlease cite this article in press as: Wilby, K.J., Wilbur, K. Cross-national analysis of e
East. Saudi Pharmaceutical Journal (2016), http://dx.doi.org/10.1016/j.jsps.2016.01.be investigated to determine facilitators and barriers for use of
narcotics in practice. In order to do this, strong collaborations
are required between regulatory bodies, health institutions,
and researchers. Future opportunities may be development
of educational programs or health promotion strategies in
order to optimize the use of these agents in these countries.
Limitations of this study should be addressed. First, data
used for this study were estimates only and did not reflect
actual narcotic consumption or prescribing data. However,
these are the best estimates available for these countries. Sec-
ondly, it is difficult to draw conclusions regarding rationale
for discrepancies observed. Instead, as discussed above, this
study generated many hypotheses for future testing relating
to narcotic utilization in Arabic speaking countries. Lastly, it
is unknown what optimal narcotic estimates should be for
these countries. Although it seems use may be suboptimal
when compared to other regions, there is no evidence that this
is actually true. Future studies should address this point by
assessing patient-level outcomes in target populations.5. Conclusions
This is the first study to examine narcotic utilization in the
Middle East. It provides a baseline assessment for capturing
trends and changes occurring over time. The primary finding
of this study, that narcotic use is low in Arabic speaking coun-
tries, should be assessed further to determine whether patients
are being adequately treated for pain. Facilitators and barriers
can be examined in other studies designed to determine why
international differences exist based on the hypotheses pre-
sented in this paper. If use is determined to be suboptimal,
health promotion and education programs can be developed
for target groups resistant to narcotic use and/or consumption
with an overall goal of optimizing patient outcomes relating to
pain management.References
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